MiMedx Group, Inc. (MDXG.OB) Announces Completion of Surgical Biologics Purchase

QualityStocks would like to highlight MiMedx Group (OTCBB: MDXG), an integrated developer, manufacturer, and marketer of patent protected biomaterial-based products. The company ("MiMedx Group") is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability.

In the company’s news yesterday,

MiMedx Group announced the completion of the purchase of Surgical Biologics. The deal was originally announced on December 21, 2010. Surgical Biologics develops bioimplants processed from human amniotic membrane. They can be used for a broad spectrum of surgical indications. Purion® is a patent pending process created by Surgical Biologics.

Surgical Biologics will operate as a wholly owned subsidiary of MiMedx Group, Inc. Surgical Biologics is a pioneer in the development of the latest advances in processing amniotic membrane tissues that provide safe, reliable, and effective implants.

The Purion® tissue processing technology produces an implant that is minimally manipulated, and its tissues are in more than 30,000 implants. The Purion® process follows strict guidelines for allograft processing established by the Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB).

MiMedx Group, Inc. affirmed their previously announced expectations for the transaction will be accretive in 2011. MiMedx continues to project the 2011 revenues to be generated from the Surgical Biologics processed tissue to be in the range of $7 million. This transaction expands MiMedx’ innovative biomaterial offerings.

Mr. Parker H. “Pete” Petit, Chairman and CEO of MiMedx Group, Inc. said, “Now, we have three biomaterial platforms to offer to physicians and our distribution networks. The Surgical Biologics’ proprietary tissue processing technology, Purion®, is a perfect complement to our existing HydroFix™ and CollaFix™ platform technologies. With this transaction, the Surgical Biologics tissue implants are now available to our sales reps and distributors. Combined with our HydroFix™ Vaso Shield and HydroFix™ Spine Shield products, the Surgical Biologics tissue implants give MiMedx a broader portfolio that immediately serves the demands and surgical preferences of practicing physicians.”

Mr. Petit added, “As our CollaFix™ products receive their initial clearances from the FDA, and our HydroFix™ products continue to receive additional clearances and certifications, the combination of the Purion® tissue processing technology for soft tissue repair could give us offerings that are extremely complementary to our planned CollaFix™ and HydroFix™ products.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.